Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  abiraterone acetate
Find trials that include:  Any drugs shown
Results 1-25 of 25 for your search:
Start Over
Enzalutamide with or without Abiraterone Acetate and Prednisone in Treating Patients with Castration-Resistant Metastatic Prostate Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A031201, NCI-2013-01737, CALGB-A031201, NCT01949337
An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CR105505, NCI-2015-00725, 56021927PCR3001, NCT02257736
Ipilimumab and Abiraterone Acetate in Treating Patients with Previously Untreated Metastatic Hormone-Resistant Prostate Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12-120, NCI-2012-01878, c12-097, NCT01688492
Alisertib, Abiraterone Acetate, and Prednisone in Treating Patients with Hormone-Resistant Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13P.128, NCI-2013-00895, 2013-02, NCT01848067
Abiraterone Acetate in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 7639, NCI-2011-03745, 0801, NCT01508234, NCT01503229
Abiraterone Acetate in Treating Patients With Hormone-Resistant Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 11-0709, NCI-2012-00116, NCT01543776
Trebananib and Abiraterone Acetate in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12C0079, NCI-2013-01535, 00003846, 120079, 751173, P11890, 9068, NCT01553188
Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-0109, NCI-2012-01149, CDR0000730114, UCCRC-IL057, 9012, IL057, NCT01576172
OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: GU12-159, NCI-2013-00088, NCT01681433
Abiraterone Acetate, Radiation Therapy, and Hormone Therapy in Treating Patients with Unfavorable-Risk Localized Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 20 to 80
Trial IDs: Pro00044071, NCI-2013-01803, NCT01717053
Abiraterone Acetate Alone, or Abiraterone Acetate and Degarelix, or Degarelix Alone in Treating Patients with Prostate Cancer Previously Treated with Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-187, NCI-2012-03130, c11-092, NCT01751451
Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0993, NCI-2013-00460, NCT01786265
Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 18 to 90
Trial IDs: 081214, NCI-2013-02403, NCT01828476
Cabazitaxel with or without Abiraterone Acetate and Prednisone in Treating Patients with Stage IV, Hormone Resistant Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 18 to 95
Trial IDs: 13-1489, NCI-2013-01356, NCT01845792
Abiraterone Acetate and Prednisone in Treating African American and Caucasian Patients with Hormone-Resistant Metastatic Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: Pro00046383, NCI-2014-00260, 212082PCR2018, DUMC Pro00046383, NCT01940276
Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D081DC00008, NCI-2015-00603, UVA97934, NCT01972217
Abiraterone Acetate without Exogenous Glucocorticoids in Treating Patients with Progressive Hormone-Resistant Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-449, NCI-2014-00950, NCT02025010
Testosterone Therapy Followed by Enzalutamide or Abiraterone Acetate in Treating Patients with Prostate Cancer That Is Progressing on Combined Androgen Therapies
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: J1416, NCI-2014-01366, CIR00006889, NA_00093344, NCT02090114
Abiraterone Acetate with or without Cabazitaxel in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-046, NCI-2014-01894, c12-108, NCT02218606
A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CR104358, NCI-2014-02010, 2014-001426-14, 56021927PCR1010, NCT02123758
Circulating Tumors Cells in Predicting Response to Abiraterone Acetate in Patients with Metastatic, Castration-Resistant Prostate Cancer
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-209, NCI-2013-02355, 212082PCR2009, NCT01961843
Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: MCC-17981, NCI-2015-00648, 15.01.0005, NCT02415621
Start Over